Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Everolimus versus mycophenolate mofetil in heart transplantation: A randomized, multicenter trial
 
  • Details

Everolimus versus mycophenolate mofetil in heart transplantation: A randomized, multicenter trial

Journal
American Journal of Transplantation
Journal Volume
13
Journal Issue
5
Pages
1203-1216
Date Issued
2013
Author(s)
Eisen H.J.
Kobashigawa J.
Starling R.C.
Pauly D.F.
Kfoury A.
Ross H.
SHOEI-SHEN WANG  
Cantin B.
Van Bakel A.
Ewald G.
Hirt S.
Lehmkuhl H.
Keogh A.
Rinaldi M.
Potena L.
Zuckermann A.
Dong G.
Cornu-Artis C.
Lopez P.
DOI
10.1111/ajt.12181
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876930437&doi=10.1111%2fajt.12181&partnerID=40&md5=e155e87307201b2feb756df67f40b67e
https://scholars.lib.ntu.edu.tw/handle/123456789/470966
Abstract
In an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to everolimus 1.5 mg or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard-dose cyclosporine (plus corticosteroids ± induction). Primary efficacy endpoint was the 12-month composite incidence of biopsy-proven acute rejection, acute rejection associated with hemodynamic compromise, graft loss/retransplant, death or loss to follow-up. Everolimus 1.5 mg was noninferior to MMF for this endpoint at month 12 (35.1% vs. 33.6%; difference 1.5% [97.5% CI: -7.5%, 10.6%]) and month 24. Mortality to month 3 was higher with everolimus 1.5 mg versus MMF in patients receiving rabbit antithymocyte globulin (rATG) induction, mainly due to infection, but 24-month mortality was similar (everolimus 1.5 mg 10.6% [30/282], MMF 9.2% [25/271]). Everolimus 3.0 mg was terminated prematurely due to higher mortality. The mean (SD) 12-month increase in maximal intimal thickness was 0.03 (0.05) mm with everolimus 1.5 mg versus 0.07 (0.11) mm with MMF (p < 0.001). Everolimus 1.5 mg was inferior to MMF for renal function but comparable in patients achieving predefined reduced cyclosporine trough concentrations. Nonfatal serious adverse events were more frequent with everolimus 1.5 mg versus MMF. Everolimus 1.5 mg with reduced-dose cyclosporine offers similar efficacy to MMF with standard-dose cyclosporine and reduces intimal proliferation at 12 months in de novo heart transplant recipients. In this study comparing cardiac transplant recipients receiving one of two doses of everolimus with reduced dose cyclosporine to patients receiving mycophenolate mofetil with standard dose cyclosporine, the authors find no effect on acute cellular rejection, modestly reduced renal function, and a reduction in the incidence and severity of lesions defined by intravascular ultrasound. See editorial by Mehra on page 1119. ? 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.
SDGs

[SDGs]SDG3

Other Subjects
cyclosporin; everolimus; mycophenolic acid 2 morpholinoethyl ester; adult; anemia; article; bacterial infection; cardiac graft rejection; constipation; controlled study; coughing; cytomegalovirus infection; death; diabetes mellitus; diarrhea; drug fever; drug induced headache; dyspnea; female; heart transplantation; human; hyperlipidemia; hypertension; immunosuppressive treatment; incidence; insomnia; interstitial lung disease; leukopenia; major clinical study; male; mouth ulcer; multicenter study; mycosis; nausea; neoplasm; neutropenia; pericardial effusion; peripheral edema; pleura effusion; priority journal; proteinuria; randomized controlled trial; stomatitis; thrombocytopenia; thrombotic thrombocytopenic purpura; tremor; wound healing; Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Asia; Australia; Biopsy; Dose-Response Relationship, Drug; Europe; Female; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Mycophenolic Acid; Myocardium; North America; Prospective Studies; Sirolimus; South America; Treatment Outcome; Ultrasonography, Interventional
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science